During the recent 2025 MSD R&D China Science Day event, Usynova Pharmaceuticals Ltd signed a cooperation agreement with MSD R&D China.

This collaboration targets co-development of small-molecule therapies for autoimmune diseases, aiming to deliver more effective and accessible treatments for conditions like psoriasis and rheumatoid arthritis.

Usynova is invested by Zhongshan Venture Capital (Zhongshan VC), a subsidiary of Zhongshan Investment Holdings. Its partnership with the global pharma leader validates the company's innovative R&D prowess. 

The deal underscores Zhongshan VC's strategic focus on biopharma, having backed cutting-edge firms like Tennor Therapeutics, Mabgeek Biotech, Zephyrm, Sinotau, Leman Biotech and Cingular Biotech in recent years.